Immunovant Inc reports results for the quarter ended in September 30 - Earnings Summary

Immunovant

07/11/2024 14:42

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 74 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -45 cents.  The mean expectation of fourteen analysts for
the quarter was for a loss of 60 cents per share. Wall Street
expected results to range from -67 cents to -46 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 74
cents​.
    * The company reported a quarterly loss of $109.12 million.
    * Immunovant Inc shares had risen by 10.2% this quarter and
lost 25.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunovant Inc is
49.00 
This summary was machine generated from LSEG data November 7 at
02:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.60          -0.74          Missed
 Jun. 30 2024      -0.53          -0.60          Missed
 Mar. 31 2024      -0.43          -0.52          Missed
 Dec. 31 2023      -0.43          -0.36          Beat